Julio Martin-Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/215381/publications.pdf

Version: 2024-02-01

35 papers 2,529 citations

257450 24 h-index 361022 35 g-index

35 all docs 35 docs citations

35 times ranked 3117 citing authors

#	Article	IF	CITATIONS
1	Induction of a Senescence-Like Phenotype in Cultured Human Fetal Microglia During HIV-1 Infection. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1187-1196.	3.6	20
2	Fate of microglia during HIVâ€1 infection: From activation to senescence?. Glia, 2017, 65, 431-446.	4.9	78
3	Hepatitis C virus core protein enhances HIVâ€1 replication in human macrophages through TLR2, JNK, and MEK1/2â€dependent upregulation of TNFâ€Î± and ILâ€6. FEBS Letters, 2014, 588, 3501-3510.	2.8	16
4	MicroRNAs and HIV-1 Infection: Antiviral Activities and Beyond. Journal of Molecular Biology, 2014, 426, 1178-1197.	4.2	96
5	Defining Differential Genetic Signatures in CXCR4- and the CCR5-Utilizing HIV-1 Co-Linear Sequences. PLoS ONE, 2014, 9, e107389.	2.5	14
6	Bioinformatic Analysis of HIV-1 Entry and Pathogenesis. Current HIV Research, 2014, 12, 132-161.	0.5	22
7	Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1132-1135.	2.2	30
8	Identification of a Smallâ€Molecule Inhibitor of HIVâ€1 Assembly that Targets the Phosphatidylinositol (4,5)â€bisphosphate Binding Site of the HIVâ€1 Matrix Protein. ChemMedChem, 2013, 8, 426-432.	3.2	34
9	RNA viruses and microRNAs: challenging discoveries for the 21st century. Physiological Genomics, 2013, 45, 1035-1048.	2.3	39
10	A Role for microRNA-155 Modulation in the Anti-HIV-1 Effects of Toll-Like Receptor 3 Stimulation in Macrophages. PLoS Pathogens, 2012, 8, e1002937.	4.7	107
11	Protective Role of Toll-like Receptor 3-Induced Type I Interferon in Murine Coronavirus Infection of Macrophages. Viruses, 2012, 4, 901-923.	3.3	70
12	MicroRNAs, Hepatitis C Virus, and HCV/HIV-1 Co-Infection: New Insights in Pathogenesis and Therapy. Viruses, 2012, 4, 2485-2513.	3.3	33
13	Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule Targeting of the HIV-1 Capsid. Journal of Virology, 2012, 86, 8472-8481.	3.4	73
14	Antiviral Breadth and Combination Potential of Peptide Triazole HIV-1 Entry Inhibitors. Antimicrobial Agents and Chemotherapy, 2012, 56, 1073-1080.	3.2	33
15	Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment. Journal of NeuroVirology, 2011, 17, 92-109.	2.1	29
16	Mortality among HIV-Infected Patients in Resource Limited Settings: A Case Controlled Analysis of Inpatients at a Community Care Center. American Journal of Infectious Diseases, 2009, 5, 219-224.	0.2	21
17	The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors. Retrovirology, 2008, 5, 89.	2.0	42
18	Broad-Spectrum Anti-Human Immunodeficiency Virus (HIV) Potential of a Peptide HIV Type 1 Entry Inhibitor. Journal of Virology, 2007, 81, 3645-3648.	3.4	42

#	Article	IF	CITATIONS
19	Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066–1087) as the fusion peptide. Virology, 2007, 358, 273-282.	2.4	60
20	Simian immunodeficiency virus envelope compartmentalizes in brain regions independent of neuropathology. Journal of NeuroVirology, 2006, 12, 73-89.	2.1	18
21	HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor. Virology, 2006, 346, 169-179.	2.4	64
22	The neuropathogenesis of AIDS. Nature Reviews Immunology, 2005, 5, 69-81.	22.7	1,002
23	California serogroup Gc (G1) glycoprotein is the principal determinant of pH-dependent cell fusion and entry. Virology, 2005, 338, 121-132.	2.4	50
24	Interaction with CD4 and Antibodies to CD4-Induced Epitopes of the Envelope gp120 from a Microglial Cell-Adapted Human Immunodeficiency Virus Type 1 Isolate. Journal of Virology, 2005, 79, 6703-6713.	3.4	18
25	Chemokine receptors in the brain: their role in HIV infection and pathogenesis. Aids, 2002, 16, 1709-1730.	2.2	44
26	Differential CD4/CCR5 Utilization, gp120 Conformation, and Neutralization Sensitivity between Envelopes from a Microglia-Adapted Human Immunodeficiency Virus Type 1 and Its Parental Isolate. Journal of Virology, 2001, 75, 3568-3580.	3.4	63
27	Determinants of Syncytium Formation in Microglia by Human Immunodeficiency Virus Type 1: Role of the V1/V2 Domains. Journal of Virology, 2000, 74, 693-701.	3.4	49
28	RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF CHRONIC HEPATITIS C. Cytokine, 2000, 12, 165-170.	3.2	24
29	ROLE OF HAEMODIALYSIS AND HEPATITIS C VIRUS INFECTION IN SPONTANEOUS AND INDUCED CYTOKINE PRODUCTION OF PATIENTS WITH CHRONIC RENAL DISEASE. Cytokine, 2000, 12, 1248-1252.	3.2	11
30	MODULATION BY BIOLOGIC RESPONSE MODIFIERS OF HEPATITIS C VIRUS ANTIGEN-INDEPENDENT CYTOKINE SECRETION IN BLOOD MONONUCLEAR CELLS. Cytokine, 1999, 11, 267-273.	3.2	13
31	Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney International, 1998, 54, 1337-1343.	5.2	131
32	EFFECTS OF THE RIBAVIRIN-INTERFERON α COMBINATION ON CULTURED PERIPHERAL BLOOD MONONUCLEAR CELLS FROM CHRONIC HEPATITIS C PATIENTS. Cytokine, 1998, 10, 635-644.	3.2	70
33	Induction of Interleukinâ€12 Production in Chronic Hepatitis C Virus Infection Correlates with the Hepatocellular Damage. Journal of Infectious Diseases, 1998, 178, 247-251.	4.0	54
34	Recombinant human granulocyte colony-stimulating factor reduces hepatitis c virus replication in mononuclear cells from chronic hepatitis c patients. Cytokine, 1996, 8, 313-317.	3.2	12
35	Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-α. Digestive Diseases and Sciences, 1994, 39, 2485-2496.	2.3	47